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BACKGROUND: Plasma biomarkers may be particularly useful as a predictor or early marker of clinical response to treatment in addition
to radiological imaging. Cytokeratin 18 (CK18) is an epithelial-specific cytokeratin that undergoes cleavage by caspases during
apoptosis. Measurement of caspase-cleaved (CK18–Asp396) or total cytokeratin 18 (CK18) from epithelial-derived tumours could
be a simple, non-invasive way to monitor or predict responses to treatment.
METHODS: Soluble plasma CK18–Asp396 and CK18 were measured by ELISA from 73 patients with advanced gastrointestinal
adenocarcinomas before treatment and during chemotherapy, as well as 100 healthy volunteers.
RESULTS: Both CK18–Asp396 and total CK18 plasma levels were significantly higher in patients compared with the healthy volunteers
(P¼0.015, Po0.001). The total CK18 baseline plasma levels before treatment were significantly higher (P¼0.009) in patients who
develop progressive disease than those who achieve partial response or stable disease and this correlation was confirmed in an
independent validation set. The peak plasma levels of CK18 occurring in any cycle following treatment were also found to be
associated with tumour response, but peak levels of CK18–Asp396 did not reach significance (P¼0.01, and P¼0.07, respectively).
CONCLUSION: Plasma levels CK18 are a potential marker of tumour response in patients with advanced gastrointestinal malignancy.
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Radiological imaging of tumours is an essential part of the practise
of oncology, with a crucial role in screening programmes and in
the diagnosis and staging of established disease. Furthermore, the
assessment of tumour size by imaging, usually with computed
tomography (CT) is a key component in determining tumour
response in clinical practice. However, the development of a
plasma biomarker to monitor treatment response would be
advantageous in terms of ease of repeated analysis and use of
resources compared with anatomical imaging. In addition, such
biomarkers might give an earlier indication of potential response
to treatment rather than the time lag, which is necessary to observe
changes in tumour size. In patients with malignancy this may
avoid administering toxic treatments with little prospect of benefit
and hence start alternative treatments earlier.
Biomarkers are defined as characteristics that are objectively
measured and evaluated as an indicator of normal biological
processes, pathological processes, or pharmacological responses to
a therapeutic intervention (Srivastava and Srivastava, 2005). The
ideal marker has high sensitivity and specificity for diagnosis; its
level should correlate with disease stage and response to treatment;
and it should be easily and reproducibly measured. Unfortunately,
the biomarkers currently available for use in the management of
solid tumours do not fulfil all these criteria and, therefore, are not
presently recommended for screening of the general population. At
present the main uses of biomarkers are in determining prognosis,
monitoring responses to treatment, and in detection of disease
recurrence.
Carcinoembryonic antigen (CEA) is a member of a class of
oncofetal antigens that are produced within the normal developing
fetus, but only in minute amounts by normal adult cells. First
described in 1965, it has become the most widely used biomarker
in gastrointestinal malignancy (Hostetter et al, 1990) and can be
measured quantitatively by an immunoradiometric assay in serum,
but owing to its lack of sensitivity in the early stages of disease it is
unsuitable for population screening. Although elevated levels were
first observed in patients with colorectal cancer, it can also be
raised in pancreatic, gastric, lung and breast cancer, and so is not
specific to colorectal cancer. It can also be elevated in a number
of benign conditions including cirrhosis, inflammatory bowel
disease, pancreatitis, and up to 3% of healthy volunteers.
Studies performed looking at serum biomarkers in gastric
adenocarcinoma have failed to provide a biomarker that is
sensitive or specific enough for population screening (Byrne
et al, 1990; Gaspar et al, 2001; Ucar et al, 2008). Biomarkers
that have been studied include CEA, carbohydrate antigen 19-9
(CA19-9) and carbohydrate antigen 72-4 (CA72-4). CA19-9 is a
monoclonal antibody raised against a colon carcinoma cell line to
detect a monosialoganglioside in patients with gastrointestinal
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scancer (Koprowski et al, 1981). It is elevated in 20–40% patients
with gastric cancer. The CA72-4 assay measures a tumour-
associated glycoprotein (TAG-72) using two monoclonal anti-
bodies. Raised serum TAG-72 levels have been observed in
33–59% patients with gastric cancer (Paterson et al, 1986; Heptner
et al, 1989).
An assay that measures circulating soluble cytokeratin 19
(CK19), CYFRA 21-1, is based on two monoclonal antibodies
to CK19 (Bodenmuller et al, 1994). CYFRA 21-1 has mostly been
used clinically in lung, and head and neck cancers (Nisman et al,
1998; Yen et al, 1998). In patients with oesophageal cancer
high preoperative levels of CYFRA 21-1 have been found to be
associated with tumour progression and poor survival outcomes
especially in patients with squamous cell carcinoma (Brockmann
et al, 2000; Shimada et al, 2003). Serum squamous cell carcinoma
antigen 2 (SCC-antigen) mRNA concentrations have been found
to be associated with pathological changes in oesophageal cancer,
but are not sensitive or specific enough to be used for screening
(Yang et al, 2008).
At present CEA can be used to monitor treatment response in
colorectal cancer in patients with elevated levels at baseline.
However, there is no such biomarker available for the management
of gastro-oesophageal cancer and it would be valuable to have a
generic biomarker that could be applicable in routine clinical
practise in monitoring treatment response in patients with both
upper and lower gastrointestinal tract cancers receiving a range of
different chemotherapy regimens.
Cytokeratin 18 (CK18) is a major component of the intermediate
filament of simple epithelial cells and epithelial-derived tumours,
and makes up approximately 5% of the total cell protein (Chou
et al, 1993). It undergoes cleavage by caspases 3, 7, and 9 during
apoptosis into proteolytic fragments (Caulin et al, 1997; Ku et al,
1997; MacFarlane et al, 2000). The monoclonal antibody, M30,
recognises a neo-epitope of CK18 (CK18–Asp396 cleavage
product) exposed after caspase-mediated cleavage during apop-
tosis, but not intact CK18 (Leers et al, 1999). A further ELISA
(M65) uses two monoclonal antibodies specific for epitopes on
CK18 to measure total (both caspase-cleaved and un-cleaved)
soluble CK18. The two ELISAs can be used in conjunction to
calculate the relative proportion of caspase-cleaved CK18 to total
CK18 in plasma (Biven et al, 2003).
The objectives of this study were to compare plasma levels of
caspase-cleaved and total soluble CK18 between healthy volunteers
and patients with advanced gastrointestinal adenocarcinomas, and
to determine if there was any correlation between changes in
plasma cytokeratin 18 levels during palliative chemotherapy and
response to treatment, and so determine if measurement of CK18
could potentially be used as a marker of clinical outcome.
We report here for the first time that plasma levels of caspase-
cleaved and total CK18 are significantly higher in patients with
gastrointestinal adenocarcinoma than in healthy volunteers,
and that plasma CK18 levels before commencing treatment, and
peak levels observed during treatment, may predict response to
chemotherapy in patients with gastrointestinal adenocarcinomas.
MATERIALS AND METHODS
Patients with gastrointestinal adenocarcinomas
This was a single-centre, prospective, open, non-randomised study
at the Beatson Oncology Centre, Glasgow, UK. Eligible patients
were those with histologically or cytologically confirmed, locally
advanced, or metastatic gastrointestinal adenocarcinoma who
were due to start systemic anticancer therapy, with either (a)
adenocarcinoma of the colon or rectum receiving fluoropyrimi-
dine-based therapy; or (b) adenocarcinoma of the oesophagus or
stomach receiving chemotherapy with a regimen containing a
fluoropyrimidine and a platinum analogue. Inclusion criteria also
included age X18 years, ability to comply with study procedures,
and life expectancy 43 months. Patients who had had systemic
anticancer therapy or radiotherapy within the previous 6 weeks
were excluded, as were women who were pregnant or lactating.
Chemotherapy was administered according to local protocols.
Disease response was assessed clinically and by computed tomo-
graphy (CT) scans performed before commencing chemotherapy
and at regular intervals during treatment (after cycles 3 and 6
for patients with gastric or oesophageal cancer and patients with
colorectal cancer receiving capecitabine, and after cycles 6 and 12
in patients with colorectal cancer receiving infusional 5-flouro-
uracil-based regimens). Disease response, as defined by the
RECIST criteria (James et al, 1999), was determined from the
radiology reports for individual patients. Epithelial toxicity experi-
enced by patients during chemotherapy was assessed by review
of an individual patient’s case records, but detailed toxicity
assessments were not prospectively recorded in this study. Sample
collection from these patients commenced in November 2004 and
is currently still ongoing. The study was approved by the West
Glasgow Hospitals Research Ethics Committee, and all patients
gave written informed consent before undertaking any study-
related procedures.
Seventy-three patients with locally advanced or metastatic
gastrointestinal adenocarcinomas were recruited in the initial
exploratory phase, including 18 patients with oesophageal
adenocarcinoma, 19 patients with gastric adenocarcinoma, and
36 patients with adenocarcinoma of the colon or rectum (Table 1).
Table 1 Table summarising patient demographic data
Characteristics Number of patients
Age
Median – 68 years 73
Range – 24–88 years
Gender
Male 41
Female 32
Primary tumour site
Colorectal 36
Oesophageal 18
Gastric 19
Disease extent
Locally advanced 11
Metastatic 60
Unknown/adjuvant 2
Chemotherapy
Capecitabine 33
Modified de Gramont 3
ECF 32
CF 3
CarboF 2
Chemotherapy cycles
Median – 4
Range – 1–12
Clinical outcome
Partial response 16
Stable disease 25
Disease progression 27
Non evaluable 5
ECF¼epirubicin/cisplatin/5-fluorouracil, CF¼cisplatin/5-fluorouracil, CarboF¼
carboplatin/5-fluorouracil.
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noma were treated with combination chemotherapy comprising
epirubicin, cisplatin, and 5-FU (ECF), three were treated with a
combination of cisplatin and 5-FU (CF), and two with carboplatin
and 5-FU (CarboF). Thirty-three of the patients with colorectal
cancer were treated with capecitabine monotherapy, and three with
infusional 5-FU and folinic acid (modified ‘de Gramont’ regimen).
Baseline pretreatment plasma samples were collected from all
patients undergoing chemotherapy. However, plasma was not
available for all time points during treatment, highlighting the
difficulties in the collection of clinical samples for this type of
study; however, baseline pretreatment plasma samples were
collected from all patients undergoing chemotherapy.
Healthy volunteers
On one occasion, blood samples were collected from 100 healthy
volunteers between November 2004 and February 2005. All
volunteers completed a short health questionnaire that recorded
current health status, previous medical history, family medical
history, current medications, and smoking and alcohol intake
history. The samples were collected anonymously and volunteers
were not followed up subsequently and did not have any further
health assessments as part of this study. This study was approved
by the West Glasgow Hospitals Research Ethics Committee, and all
volunteers gave written informed consent.
Blood collection and preparation
Twenty milliliters of blood were collected into tubes containing
EDTA (Greiner Bio-one Vacuette) before starting chemotherapy
(baseline) and before administration of each subsequent course of
chemotherapy (day 1) until discontinuation of systemic therapy.
Additional 20ml samples were collected at various time points
during chemotherapy courses in selected patients, with the time
points dependent on the specific chemotherapy regimen (day 2 for
infusional 5-flourouracil regimens in colorectal cancer, and on
days 2, 8, and 15 in patients with gastric or oesophageal cancer
receiving continuous infusional 5-flourouracil). The time points
for sample collection were chosen to coincide with patients’
scheduled appointments for treatment, which depended on the
regimen received. Blood samples (20ml) were collected into tubes
containing EDTA (Greiner Bio-one Vacuette) on one occasion
from the 100 healthy volunteers.
Plasma was separated within 2h of collection by centrifuging the
whole blood sample at 1500g for 10min at 201C. The supernatant
was then removed, placed in a separate 15ml falcon tube and
centrifuged again using the above conditions. The resulting
supernatant was then aliquoted into Eppendorf tubes (Eppendorf
AG, Hamburg, Germany) and immediately frozen at  701C until
analysis.
Assay methods
Samples were assayed in duplicate for CK18–Asp196 using
the M30-Apoptosense ELISA (PEVIVA AB, Bromma, Sweden),
for which the normal range is p180Ul
 1 where 1 unit equals
1.24pmol (manufacturer’s brochure), and for total soluble CK18
using the M65-ELISA (PEVIVA) according to the manufacturer’s
instructions and the final result used for further analysis was the
mean of the values from the duplicates. In brief, 25ml of sample
was added to each well, followed by 75ml of HRP-conjugated
monoclonal antibody. The samples were then incubated for 4h
at room temperature with constant shaking, after which excess
unbound conjugate was removed by five washing steps. Colour
development was then achieved by the addition of 200mlo f3 ,
3,5,50-tetramethyl-benzidine solution, followed by incubation for
20min in the dark. The reaction was stopped by the addition of
50ml of 1.0 M sulphuric acid and the absorbance measured in a
microplate reader at 450nm. Through plotting a standard curve
of known concentrations of M30 antigen standards supplied in
the kit against absorbance, the amount of antigen in the controls
and unknown samples can be calculated by interpolation.
Sample dilution was performed according to the manufacturer’s
instructions.
Study design and sample size
The objectives of this study were to compare plasma levels of
CK18–Asp196 and total soluble CK18 between healthy volunteers
and patients with advanced gastrointestinal adenocarcinomas, to
determine if there was any correlation between changes in plasma
cytokeratin 18 levels during palliative chemotherapy and tumour
response, and so determine if measurement of CK18 could
potentially be used as a marker of clinical outcome. Other
variables considered within the patient population included age,
gender, disease extent at baseline, tumour marker (CEA) assess-
ment (patient population only), epithelial toxicity and chemo-
therapy regimen received.
The sample size of 73 cancer patients was initially assessed in an
exploratory study as this was the number of patient samples
available. As the subsequent statistical analysis yielded positive
correlations, a validation study was then performed using an
additional 53 patients, a power analysis was performed to ensure
that this number was adequate based on the associations observed
in the exploratory study.
It was considered inappropriate to perform a survival analysis
for this heterogenous group of patients with either advanced
gastro-oesophageal or colorectal cancers receiving palliative
chemotherapy with a number of chemotherapy regimens. Tumour
response was considered a more robust indicator of clinical
outcome for the purposes of this study.
Statistical analysis methods
The distribution of the CK18, CK18–Asp396 and CEA values were
markedly skewed so these variables were logged in all analyses.
Where there were two classifying groups (e.g., gender) the Mann–
Whitney U-test was used to compare these variables (or changes
between variable values); when there were more than two groups
(e.g., tumour site) the Kruskal–Wallis test was used. Spearman’s
rank correlation test was used when determining an association
between either CK18 or CK18–Asp396 and age. The replicate
variability in the assays was estimated from all the replicate results
available in the study.
RESULTS
Total soluble and caspase-cleaved CK18 levels: healthy
volunteers
Plasma CK18–Asp396 levels within 100 normal healthy volunteers
were assessed using the M30 Apoptosense ELISA. Within the
population studied there was a wide range of values, from 51 to
849Ul
 1, with a median of 121Ul
 1. The values were inde-
pendent of age (P¼0.80) and gender (P¼0.21). The range in
female patients was 51–849Ul
 1 and that in male patients was
79–616Ul
 1. The total soluble CK18 levels were also determined
for the 100 normal healthy volunteers using the M65 ELISA and as
for the CK18–Asp396, there was a wide range in total soluble CK18
levels (161–899Ul
 1), with a median of 312Ul
 1. As for CK18–
Asp396, the range in females was greater compared to the male
patients (167–899 vs 161–630Ul
 1). Again these values were not
significantly associated with age (P¼0.45) or gender (P¼0.06).
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gastrointestinal adenocarcinomas
Baseline CK18–Asp396 and CK18 levels were measured in 73
patients with advanced gastrointestinal adenocarcinoma. The
median CK18–Asp396 value was 207Ul
 1 (range 35–2535Ul
 1)
and the median CK18 value was 717Ul
 1 (range 206–7747Ul
 1).
The pretreatment plasma levels of both CK18–Asp396 and CK18
were significantly higher (P¼0.015 for patients with gastric cancer
and Po0.001 for patients with oesophageal and colorectal cancer)
in the plasma samples of patients with all types of gastrointestinal
adenocarcinoma examined compared with plasma samples from
healthy volunteers (Figure 1 and Table 2).
Receiver operating characteristic (ROC) curves for CK18–
Asp396 and CK18 distinguished between patients with advanced
gastrointestinal malignancy and healthy volunteers (Figure 2).
Pooled data for all 73 patients demonstrated that CK18–Asp396
has a sensitivity of 27% at a specificity of 90% in distinguishing
patients with advanced gastrointestinal malignancy and healthy
volunteers. Similarly, CK18 has a sensitivity of 71% at a specificity
of 90% in distinguishing between patients with advanced
gastrointestinal malignancy and healthy volunteers. These results
suggest that CK18 may be a better biomarker than CK18–Asp396
in distinguishing between plasma from patients with cancer and
healthy volunteers, but that both markers may have limited use as
a diagnostic marker.
Patients’ disease extent at baseline was associated with plasma
CK18 and CK18–Asp396. Both the baseline plasma CK18–Asp396
and CK18 levels were significantly higher in the patients with
metastatic disease compared with those with locally advanced
disease; CK18–Asp396, median 210Ul
 1 (range 58–2535Ul
 1) vs
164Ul
 1 (range 35–333Ul
 1), CK18, median 833Ul
 1 (range
260–7747Ul
 1) vs 452Ul
 1 (range 269–746Ul
 1)( P¼0.014 and
P¼0.011, for CK18–Asp396 and CK18, respectively).
Correlation of plasma CK18 levels with tumour response
Objective tumour response data was available for 68 out of the
73 patients, and included 16 patients with partial responses,
25 patients with stable disease and 25 patients with progressive
disease. A further two patients had rapid clinical disease
progression which occurred before radiological disease assess-
ment and were deemed to have progressive disease. Five
others were non-evaluable as four had missing scan data and
one patient was receiving adjuvant treatment. Patients’ case
notes were also reviewed to document the timing and grade
of epithelial toxicity observed during chemotherapy. This
was then correlated with changes in plasma CK18 and CK18–
Asp396.
The CK18–Asp396 and CK18 median plasma levels at baseline
were higher (289 vs 194Ul
 1 for CK18–Asp396, and 1021 vs
618Ul
 1 for CK18) in patients who subsequently developed
progressive disease during treatment (n¼27) compared with
patients who subsequently developed partial response or stable
disease (n¼41), although was only statistically significant for
CK18 (P¼0.125, P¼0.009, for CK18–Asp396 and CK18, respec-
tively, see Figure 3). There is an overall sensitivity of 22% at a
specificity of 90% for CK18–Asp396 and an overall sensitivity of
19% at a specificity of 90% for CK18 baseline plasma levels in
distinguishing between patients who will subsequently progress
through chemotherapy and those who will have partial response/
stable disease with treatment.
The plasma levels of CK18–Asp396 and CK18 were examined
for each patient and the maximum level (or peak level) observed
during treatment, defined as the maximum level that had
been observed for each patient during any cycle of treatment,
was compared with tumour response. Peak levels of CK18 were
found to be associated with tumour response, but peak levels of
CK18–Asp396 did not reach significance (P¼0.01, and P¼0.07,
respectively: Figure 4A and B).
Comparison of the different chemotherapy regimens (ECF and
capecitabine) and tumour response is confounded by comparing
responses between the two different tumour groups (upper
gastrointestinal cancer and colorectal cancer). Chi-squared test
analysis of the relationship between the chemotherapy regimens
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Figure 1 Plasma CK18–Asp396 and CK18 levels in patients vs healthy
volunteers, and in different tumour types vs healthy volunteers. (A) Box
plot demonstrating significantly higher plasma CK18–Asp396 and CK18
levels in patients with advanced gastrointestinal adenocarcinomas com-
pared with healthy volunteers (Po0.001). (B) Box plot demonstrating
significantly higher baseline CK18–Asp396 and CK18 plasma levels in
patients with advanced esophageal (Po0.001, for CK18–Asp396 and
CK18), colorectal (Po0.001 for CK18–Asp396 and CK18) and gastric
(P¼0.015, Po0.001, for CK18–Asp396 and CK18, respectively) cancer
compared with healthy volunteers. Ul
 1 is defined according to the
manufacturer’s brochure where 1 unit equals 1.24pmol. Outliers are
shown by asterisk.
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disease) found no relationship between chemotherapy regimen
and tumour response. Also, from the analysis the association
between baseline plasma CK18–Asp396, total CK18 and response
does not appear to be greatly affected when the chemotherapy
regimen is allowed for.
Various patient demographic factors, including age, gender, and
baseline disease extent (either locally advanced or metastatic
disease at commencement of chemotherapy) were then analysed
with treatment outcome to chemotherapy, but no correlation was
found (P¼0.514, P¼0.149, and P¼0.934, for age, gender, and
disease extent, respectively). Similarly, there was no significant
association between baseline plasma CK18–Asp396 and CK18
levels and patient’s age (P¼0.345, P¼0.112 for CK18–Asp396 and
CK18, respectively) and gender (P¼0.519, P¼0.257 for CK18–
Asp396 and CK18, respectively). In addition, a straightforward
visual inspection of the data revealed no obvious association
between the timing of epithelial toxicity experienced and the
occurrence of peak values of plasma CK18 and CK18–Asp396.
However, the sampling for CK18 measurement was within the first
2 days of each cycle of treatment whereas epithelial toxicity is
clinically observed mid-way through treatment cycles, although
epithelial damage at the cellular level in normal tissues may well
occur at the same time as in the cancer but become clinically
apparent later during the treatment cycle.
In summary, plasma levels of CK18 at baseline are significantly
higher in patients with progressive disease compared to patients
with partial response/stable disease, and peak plasma levels of
CK18 observed during treatment are associated with treatment
response. Differences in plasma CK18–Asp396 and CK18 levels do
not significantly associate with the patient’s age, gender or the
extent of disease at baseline.
Validation study
A validation study was performed to see if baseline plasma levels of
CK18–Asp396 and CK18 showed a reproducible correlation with
treatment response in an additional cohort of 53 patients with
advanced gastrointestinal malignancy. This included 25 patients
with colorectal cancer, 15 with gastric cancer, and 13 with
oesophageal cancer. Twenty-five of the patients with gastric or
oesophageal adenocarcinoma were treated with combination
chemotherapy comprising epirubicin, cisplatin, and 5-FU (ECF),
one was treated with a combination of cisplatin and 5-FU (CF), one
with carboplatin and 5-FU (CarboF) and one with epirubicin,
carboplatin, and 5-FU (ECarboF). Fifteen of the patients with
colorectal cancer were treated with capecitabine monotherapy, two
with infusional 5-FU and folinic acid (modified ‘de Gramont’
regimen), five with combination chemotherapy comprising
capecitabine and oxaliplatin, one with oxaliplatin and 5-FU
(FOLFOX) and two with capecitabine, oxaliplatin, and cetuximab
(see Table 3).
Objective tumour response data was available for all of the 53
patients, and included eight patients with partial responses, 24
patients with stable disease and 12 patients with progressive
disease. A further nine patients had rapid clinical disease
Table 2 Table summarising the median and range of CK18–Asp396 and CK18 plasma levels in healthy volunteers and in patients with gastrointestinal
adenocarcinoma
CK18–Asp396 median
value and range (U/l)
CK18 median value
and range (U/l)
P-value for CK18–Asp396 between
tumour and healthy volunteers
P-value for CK18- between
tumour and healthy volunteers
Healthy volunteers 121 (51–849) 312 (161–899) — —
Gastric cancer 183 (35–1569) 746 (206–3313) P¼0.015 Po0.001
Oesophageal cancer 204 (86–2535) 672 (266–7747) Po0.001 Po0.001
Colorectal cancer 213 (81–1936) 780 (267–3482) Po0.001 Po0.001
Source of the curve
CK18–Asp396
CK18
Reference line
0.0 0.2 0.4 0.6 0.8 1.0
1 - specificity
1.0
0.8
0.6
0.4
0.2
0.0
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Figure 2 ROC curves for CK18–Asp396 and CK18 distinguishing
between patients with advanced gastrointestinal malignancy and healthy
volunteers. Outliers are shown by asterisk.
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Figure 3 Baseline plasma levels of CK18–Asp396 and CK18 correlated
with treatment outcome. Box plot demonstrating baseline CK18–Asp396
and CK18 plasma levels in patients who developed progressive disease
through chemotherapy and partial response/stable disease. The CK18 level
is significantly higher in patients with progressive disease (P¼0.009, Mann–
Whitney), (NE stands for non-evaluable treatment outcome). Ul
 1 is
defined according to the manufacturer’s brochure where 1 unit equals
1.24pmol. Outliers are shown by asterisk.
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sprogression, which occurred before radiological disease assess-
ment and were deemed to have progressive disease.
The validation group showed overlapping range and similar
median values for CK18–Asp396 and CK18 as the original test
set (median 158Ul
 1, range 56–18786Ul
 1 for CK18–Asp396
and median 660Ul
 1 and range 235–19702Ul
 1 for CK18). In the
validation group, baseline plasma levels of both CK18–Asp396 and
CK18 were again significantly associated with treatment outcomes
(partial response/stable disease vs disease progression: P¼0.028,
P¼0.003, respectively).
DISCUSSION
This is the first report, to our knowledge, documenting that the
mean plasma pretreatment CK18 level is higher in patients with
advanced gastrointestinal malignancy compared with healthy
volunteers (Figure 1, Table 2). The groups were not age-matched,
but levels of CK18 do not correlate with age. It is of note that the
range of both plasma CK18–Asp396 and CK18 was wide in the
healthy volunteers (Figure 1). Alcohol intake is known to increase
caspase-cleaved CK18 values in serum as alcohol may cause
apoptosis of liver cells (Natori et al, 2001). Other studies have also
shown that viral illness, chronic hepatitis, and sepsis will increase
levels of caspase-cleaved CK18 detected by the M30 Apoptosense
ELISA kit (Bantel et al, 2004; Roth et al, 2004; Kronenberger et al,
2005). Thus the wide variation in caspase-cleaved CK18 values in
healthy volunteers could possibly be due to intercurrent viral
illness or alcohol consumption; however, the entry criteria for the
healthy volunteer part of the study stated that they should have no
significant past medical history, no evidence of intercurrent illness
and no concomitant medications. A Mann–Whitney test was
used to establish if an alcohol consumption of o or 4 10 units per
week affected the plasma CK18 levels in the healthy volunteers.
The cutoff of 10U per week was selected as this is below the
recommended weekly consumption for both men and women.
Within this group, alcohol consumption was not found to be
associated with elevated plasma levels of either CK18–Asp396 or
total soluble CK18 (P¼0.91 and P¼0.98, respectively).
The group of healthy volunteers was not followed up long-term
and so it is unknown whether they subsequently developed any
pathology to account for the variation in levels observed. As there
is a significant overlap in plasma CK18–Asp396 levels between the
healthy volunteers and cancer patients, it may be challenging to
draw conclusions in individual cases.
After our sample collection from healthy volunteers had been
completed, it was reported that elevated serum levels of caspase-
cleaved CK18 may be an indicator of myocardial damage
(Adlbrecht et al, 2007). However, healthy volunteers were ineligible
if they had significant past or current illnesses. Although it was
feasible that the patients with gastrointestinal cancer could
have developed myocardial damage during the course of the
study, these chemotherapy regimens are used with caution in
patients with significant cardiac co-morbidities and we believe that
it is unlikely that myocardial damage accounts for the levels
of plasma CK18 observed.
We report in this study that the plasma CK18 level before
commencing chemotherapy may predict treatment outcome in
patients with advanced gastrointestinal adenocarcinoma. The
patients with comparatively higher baseline levels of plasma
CK18 tended to have higher levels of disease progression through
chemotherapy compared to patients with lower baseline levels
CK18–Asp396
CK18
Treatment outcome
Partial/stable Progressive
* *
* * *
*
*
U
/
L
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Figure 4 Peak plasma levels of CK18–Asp396 and CK18 correlated
with clinical response (partial response/stable disease vs progressive
disease). Box plot demonstrating peak plasma levels of CK18–Asp396
and CK18 in patients who developed progressive disease through
chemotherapy compared with those who achieved a partial response/
stable disease. The peak CK18 level is significantly with response (P¼0.01).
Outliers are shown by asterisk.
Table 3 Table summarising the patient demographic data in the
validation study
Characteristics Number of patients
Age
Median 70 years
Range 41–86 years
Gender
Male 31
Female 22
Primary tumour site
Colorectal 25
Oesophageal 13
Gastric 15
Disease extent
Locally advanced 14
Metastatic 39
Chemotherapy
Capecitabine 15
Modified de Gramont 2
XELOX+/ cetuximab 2
FOLFOX 1
ECF 25
CF 1
Carbo F 1
ECarboF 1
Chemotherapy cycles
Median 2
Range 1–12
Clinical outcome
Partial response 8
Stable disease 24
Disease progression 21
XELOX¼oxaliplatin/capecitabine; FOLFOX¼oxaliplatin/infusional 5-flourouracil;
ECF¼epirubicin/cisplatin/5-flourouracil; CF¼cisplatin/5-flourouracil; CarboF¼
carboplatin/5-flourouracil; EcarboF¼epirubicin/carboplatin/5-flourouracil.
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and potential for access to the circulatory system, as patients with
metastatic disease had higher baseline levels of CK18 and CK18–
Asp396 than those with locally advanced disease. However, when
baseline disease extent as determined by CT scanning was
correlated with treatment outcome, a statistically significant
association was not found. This suggests that the baseline plasma
CK18–Asp396 and CK18 levels may give an indication of both
tumour burden and also the amount of cell death that is occurring,
whether this is as a result of chemotherapy or as part of the
ongoing disease process.
Pretreatment levels of CK18–Asp396 in the sera of patients with
primary breast cancer, (n¼152), recurrent breast cancer (n¼49)
or normal controls (n¼82) (Ueno et al, 2003), demonstrated that
patients with primary cancer had higher serum CK18–Asp396
levels than the normal controls (P¼0.0001) and that patients with
recurrent cancer had higher serum CK18–Asp396 levels than both
the primary breast cancer patients and the normal controls
(median values 180.5 vs 165.7 vs 156.2Ul
 1 (Po0.0001 and
P¼0.008, respectively)). In addition, in patients with recurrent
cancer the serum CK18–Asp396 level correlated with the number
of involved organs, or burden of disease (P¼0.041). In another
study in patients with recurrent breast cancer (n¼32) receiving
chemotherapy with cyclophosphamide, epirubicin and 5-flourour-
acil or docetaxel (Biven et al, 2003), an index was calculated for
each patient based on the difference between the maximum CK18–
Asp396 level observed during treatment and the pretreatment
level. Increases in serum CK18–Asp396 of at least 50% were
significantly associated with clinical response (P¼0.0001). More
recently, the use of CK18 as a biomarker for monitoring
chemotherapy-induced cell death in breast cancer has been
published (Olofsson et al, 2007). In this study, both CK18–
Asp396 and total CK18 were assessed using the ELISAs and drug-
induced release of CK18 examined from breast carcinoma cells and
tissue. Serum CK18 levels were then determined in 61 patients with
breast cancer receiving either docetaxel or cyclophosphamide/
epirubicin/5-flourouracil (CEF) chemotherapy. The results showed
that CK18–Asp396 was released from cell and tissue cultures to the
extracellular compartment and that the protein complexes were
stable, suggesting that CK18-based assays would be applicable in
clinical studies. In patients with breast cancer, docetaxel was found
to induce increased levels of CK18–Asp396, indicating that the
primary mode of cell death was apoptosis. In contrast, CEF
induced increased levels of total CK18, indicating that the primary
mode of cell death in these patients was necrosis. Also, the level of
increase of total CK18 at 24hrs post-treatment correlated with
clinical response to CEF (Po0.0001). Recently published studies of
patients with hormone refractory prostate cancer (n¼82) receiv-
ing palliative chemotherapy (Kramer et al, 2006) show significant
increases in CK18–Asp396 usually between days 5 and 7 of each
treatment cycle.
Two studies were recently published evaluating CK18 in patients
with colorectal cancer. The first studied pre- and post-operative
serum levels of CK18–Asp396 in 31 patients (Ausch et al, 2009). It
also assessed serum levels of CK18–Asp396 in 10 patients
receiving combination chemotherapy with oxaliplatin/capecita-
bine. The results showed that peri-operative levels of CK18–Asp
396 correlated significantly with tumour recurrence (P¼0.016),
but that increases in CK18–Asp 396 observed during chemother-
apy did not correlate with response. The second study measured
pre- and post-operative plasma levels of CK18–Asp396 and total
CK18 in 49 patients with colorectal cancer and correlated the levels
with patient and tumour characteristics, and survival outcomes
(Koelink et al, 2009). The results showed that peri-operative
plasma levels of both CK18–Asp396 and total CK18 were
correlated with disease stage and were predictive of disease-free
survival independent of tumour stage. Also the ratio of plasma
CK18–Asp396/total CK18 which decreased with tumour progres-
sion, was also predictive of disease-free survival.
CK18–Asp 396 may also be applicable as a pharmacodynamic
biomarker in phase I clinical trials of novel non-cytotoxic
molecularly targeted anticancer therapies, with which objective
tumour responses, as determined by a reduction in tumour
dimensions by conventional imaging techniques, may not be
observed. For example, our group has previously demonstrated
that disease stabilisation was associated with CK18–Asp 396
plasma levels in patients with advanced solid tumours treated in a
phase 1 clinical trial of the novel hydroxamate histone deacetylase
inhibitor, belinostat (Steele et al, 2008).
It is of note that since our study started several papers have been
published regarding sample-handling protocols for determination
of serum and plasma CK18. Delays of greater than 4h in sample
acquisition and processing resulted in a significant increase in
CK18–Asp396 levels. This effect was minimised by incubating the
sample on ice. Furthermore, prolonged storage (46 months) at
 801C resulted in higher levels of CK18–Asp396. The recommen-
dation was that serum rather than plasma should be used to
decrease the variation between the duplicate assays (Greystoke
et al, 2008). Although plasma was used in our study, we had a
robust standard operating protocol for sample acquisition that
ensured all samples were processed and frozen to  801C within 2h
of venesection. Other studies published have reported the stability
of both CK18–Asp396 and total soluble CK18 in plasma from
cancer patients stored at  801C for over 2 years (Cummings et al,
2007). The plasma used in our study had been kept at  801C
for o2 years and care was taken to use samples that had not
been repeatedly freeze thawed.
In conclusion, the results from our study suggest that measuring
baseline and peak plasma levels of CK18 in patients receiving
palliative chemotherapy for advanced gastrointestinal malignancy
may help predict individual outcomes to therapy. However, a
larger prospective clinical study is required to validate these
results.
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